Asahi Kasei Pharma has completed the construction of a new manufacturing facility at its pharmaceutical plant in Fuji, Shizuoka, Japan.

The new facility will be used for the manufacture of the active ingredient of Recomodulin™ thrombomodulin agent¹, one of Asahi Kasei Pharma’s core products. The addition of the new manufacturing facility to its Fuji Pharmaceuticals Plant will enable Asahi Kasei Pharma to enhance its ability to assure reliable supply of Recomodulin™ while reinforcing the company’s capability to comply with increasingly stringent standards for good manufacturing practices (GMP)².

Asahi Kasei Pharma will continue to further enhance its manufacturing capabilities for the stable provision of high-quality products for patients.

1. ¹ Recomodulin™ is a thrombomodulin agent manufactured using genetic recombination technology. It acts as an anticoagulant by suppressing the activity and production of thrombin, a blood coagulation factor.
2. ² GMP is a set of standards for the manufacturing and quality control of pharmaceuticals and related products to ensure that products are manufactured at stable high quality as approved. GMP regulates the entire manufacturing process from the receiving of raw materials to the shipment of finished products, including standards for the design of buildings and the placement of machinery to minimize the risk of human error.

Outline of the new manufacturing facility

Location

Fuji, Shizuoka, Japan

Structure

Three stories above ground

Total floor area

Approx. 4,400 m²

Completion

June 2016

Start-up

April 2017 (scheduled)

Investment

Approx. ¥4.5 billion